In December 2016, the CMA found that both Pfizer and Flynn had abused their respective dominant positions in markets for the manufacture and distribution of phenytoin sodium capsules (a treatment for epilepsy) manufactured by Pfizer. It imposed a record fine for a UK competition infringement of £84.2 million on Pfizer.